```html

Zoster Ophthalmicus – A Patient‑Focused Guide

Overview

Zoster ophthalmicus (ZO) is a manifestation of herpes zoster (shingles) that involves the ophthalmic branch (V1) of the trigeminal nerve. When varicella‑zoster virus (VZV) reactivates in this distribution, it can affect the eye, eyelid, conjunctiva, cornea, and surrounding skin.

Anyone who has had chickenpox or received the varicella vaccine carries latent VZV in sensory ganglia. Reactivation is most common in older adults, but immunocompromised individuals of any age are also at risk.

• Incidence: Approximately 10–20 % of all shingles cases involve the V1 distribution, and of those, 50–70 % develop ocular involvement (CDC, 2023).
• Age distribution: Incidence rises sharply after age 50, reaching about 1–2 cases per 1,000 persons per year in adults >70 years old.
• Gender: Slight female predominance (≈55 % of cases), likely reflecting higher overall shingles rates in women.

Symptoms

Symptoms usually appear in two phases: prodromal (pre‑rash) and acute (rash). Not all patients experience every sign.

Prodromal (1–5 days before rash)

• Eye pain or pressure – often described as burning, throbbing, or a deep ache behind the eye.
• Headache – usually localized to the forehead or temple on the affected side.
• Photophobia – heightened sensitivity to light.
• Vision changes – blurred vision, floaters, or a sensation of “grittiness.”
• Facial tingling or numbness in the V1 distribution (forehead, scalp, upper eyelid).

Acute rash phase (2–7 days after prodrome)

• Grouped vesicles on an erythematous base – typically follow the V1 dermatome: forehead, scalp, upper eyelid, bridge of the nose, and sometimes the tip of the nose (Hutchinson’s sign).
• Conjunctival injection – red eye due to inflammation.
• Keratitis – painful corneal ulcerations that may cause a “doughnut” shape of opacities.
• Episcleritis or scleritis – inflammation of the white part of the eye, causing deep ache.
• Uveitis – inflammation of the middle eye layer, leading to photophobia, blurred vision, and possible swelling of the iris.
• Eyelid edema and crusting – swelling, tearing, and difficulty closing the eye.
• Hutchinson’s sign – lesions on the tip or side of the nose; strongly predicts ocular involvement.

Causes and Risk Factors

Underlying cause

Zoster ophthalmicus results from reactivation of latent varicella‑zoster virus within the trigeminal (cranial nerve V) ganglion. The virus travels down the ophthalmic branch to skin and ocular structures, causing inflammation and vesicular lesions.

Key risk factors

• Age ≥ 50 years – immune senescence reduces VZV-specific cellular immunity.
• Immunosuppression – HIV infection, organ transplantation, chemotherapy, long‑term corticosteroids, biologics (e.g., TNF‑α inhibitors).
• Stress or trauma – physical or emotional stress can trigger reactivation.
• Chronic diseases – diabetes, chronic kidney disease, or respiratory illness.
• Previous shingles episodes – having had shingles elsewhere increases risk of a second episode.
• Absence of vaccination – those who have not received the recombinant zoster vaccine (Shingrix) have higher risk.

Diagnosis

Prompt diagnosis is essential to protect vision.

Clinical evaluation

• History – prodromal eye pain, rash onset, recent immunosuppression.
• Physical exam – inspection of skin for vesicular rash in the V1 dermatome; slit‑lamp examination to assess conjunctiva, cornea, and anterior chamber.
• Hutchinson’s sign – presence of nasal tip lesions signals ocular involvement.

Laboratory and ancillary tests

• Polymerase chain reaction (PCR) of lesion swab – detects VZV DNA; useful when the rash is atypical.
• Direct fluorescent antibody (DFA) testing – rapid identification of VZV in skin scrapings.
• Serology – generally not required, as most adults are VZV‑IgG positive.
• Ophthalmic imaging – anterior segment optical coherence tomography (AS‑OCT) or fluorescein staining to evaluate corneal ulcer depth.

Treatment Options

Therapy aims to (1) halt viral replication, (2) control inflammation, and (3) protect ocular structures.

Antiviral medications (must start within 72 hours of rash onset)

• Acyclovir 800 mg orally five times daily for 7–10 days.
• Valacyclovir 1 g orally three times daily (preferred for better bioavailability).
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir (10 mg/kg every 8 h) is reserved for immunocompromised patients or those with severe ocular disease.

Corticosteroids

• Topical prednisolone acetate 1 % drops (q.i.d.–q.i.d.) for anterior uveitis or keratitis under ophthalmology supervision.
• Systemic oral prednisone 40–60 mg daily for 5–10 days may be added in severe inflammatory cases, tapering as symptoms improve.

Adjunctive ocular therapy

• Lubricating eye drops (artificial tears) – relieve dryness and prevent corneal abrasions.
• Cycloplegic agents (e.g., cyclopentolate) – reduce painful ciliary spasm in uveitis.
• Antibiotic eye drops – prophylactic use if corneal ulceration is present (e.g., moxifloxacin 0.5 % q.i.d.).

Surgical/interventional options (rare)

• Therapeutic keratoplasty – corneal transplant for severe, sight‑threatening scarring.
• Amniotic membrane graft – promotes healing of persistent epithelial defects.

Lifestyle and supportive care

• Rest and stress reduction to aid immune recovery.
• Hydration and balanced nutrition (vitamins A, C, E support mucosal health).
• Avoid rubbing the eye; use protective eyewear if light sensitivity is severe.

Living with Zoster Ophthalmicus

Daily management tips

• Medication adherence – set alarms or a pill‑box to complete the full antiviral course.
• Eye hygiene – gently clean crusts with sterile saline; use clean cotton pads; discard after each use.
• Protective eyewear – wear sunglasses to limit photophobia and protect the cornea from wind/dust.
• Follow‑up schedule – see an ophthalmologist within 24–48 hours of diagnosis, then weekly until lesions resolve.
• Monitor vision – keep a simple log of visual acuity (e.g., ability to read a newspaper) and report any sudden changes.
• Vaccination reminders – after recovery, discuss the Shingrix vaccine (recommended ≥50 years) to prevent recurrence.

Psychosocial considerations

Post‑herpetic neuralgia and facial scarring can affect self‑esteem. Consider counseling, support groups, or referral to a pain specialist if chronic facial pain persists beyond 3 months.

Prevention

• Recombinant zoster vaccine (Shingrix) – two‑dose series, >90 % efficacy in adults ≥50 years; recommended for immunocompetent persons and, per CDC 2022 guidance, for select immunocompromised groups.
• Varicella vaccination – for adults without prior chickenpox exposure; reduces primary VZV infection risk.
• Immune health – control diabetes, maintain healthy weight, limit alcohol, avoid smoking.
• Stress management – regular exercise, mindfulness, adequate sleep strengthen cellular immunity.
• Prompt treatment of early shingles – if a non‑ocular shingles rash appears, initiate antivirals promptly to reduce V1 spread.

Complications

If left untreated or inadequately managed, ZO can lead to serious, sometimes irreversible, eye damage.

• Vision loss – from corneal scarring, stromal keratitis, or optic neuritis.
• Glaucoma – secondary to chronic intra‑ocular pressure elevation from uveitis.
• Post‑herpetic neuralgia – persistent facial pain lasting >3 months.
• Secondary bacterial infection – ulcerated lesions can become infected, requiring antibiotics.
• Retinal necrosis – rare but devastating, leading to permanent visual field defects.
• Hutchinson’s sign–related complications – indicates higher likelihood of corneal involvement.

When to Seek Emergency Care

---

References: CDC. Shingles (Herpes Zoster) – 2023; Mayo Clinic. Zoster Ophthalmicus; National Institute of Allergy and Infectious Diseases (NIH) – VZV latency review, 2022; WHO. Global burden of herpes zoster, 2021; Cleveland Clinic. Eye Emergencies; JAMA Ophthalmology. Antiviral treatment outcomes, 2022.

```